Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 146-161

  Lampropoulou, Vicky ^a   Calderon Gomez, Elisabeth ^a   Roch, Toralf ^a   Neves, Patricia ^a   Shen, Ping ^a   Stervbo, Ulrik ^a   Boudinot, Pierre ^b   Anderton, Stephen M ^c   Fillatreau, Simon ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b INRA Institut National de la Recherche Agronomique   (France)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmunity; B cells; Feedforward loop; Immunoregulation; Interleukin 10; Toll like receptor

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; CD40 ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TH1 CELL;

EID: 73249114021     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00855.x     Document Type: Review

References (119)

1. Edwards JC, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 2581.
2. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006 24 : 467 496.
3. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002 16 : 219 230.
4. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002 3 : 944 950.
5. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006 176 : 705 710.
6. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008 8 : 391 397.
7. Anderton SM, Fillatreau S. Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 2008 4 : 657 666.
8. Lampropoulou V, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008 180 : 4763 4773.
9. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007 13 : 1365 1368.
10. Hoehlig K, et al. Immune regulation by B cells and antibodies a view towards the clinic. Adv Immunol 2008 98 : 1 38.
11. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997 186 : 1749 1756.
12. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996 184 : 2271 2278.
13. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000 12 : 597 605.
14. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003 197 : 489 501.
15. Wagner U, Kaltenhauser S, Pierer M, Wilke B, Arnold S, Hantzschel H. B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response. Arthritis Res 2002 4 : R1.
16. Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 2005 32 : 378 379.
17. Renaud S, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003 27 : 611 615.
18. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008 57 : 714 715.
19. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007 56 : 2715 2718.
20. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004 172 : 3422 3427.
21. Duddy M, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007 178 : 6092 6099.
22. Kuchroo VK, Martin CA, Greer JM, Ju ST, Sobel RA, Dorf ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993 151 : 4371 4382.
23. Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005 6 : 1133 1141.
24. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001 167 : 1081 1089.
25. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992 258 : 1156 1159.
26. Dalwadi H, et al. B cell developmental requirement for the G alpha i2 gene. J Immunol 2003 170 : 1707 1715.
27. Wei B, et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA 2005 102 : 2010 2015.
28. Wei B, et al. Integration of B cells and CD8+ T in the protective regulation of systemic epithelial inflammation. Clin Immunol 2008 127 : 303 312.
29. Miyazaki D, Kuo CH, Tominaga T, Inoue Y, Ono SJ. Regulatory function of CpG-activated B cells in late-phase experimental allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009 50 : 1626 1635.
30. Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 2005 22 : 467 477.
31. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000 192 : 475 482.
32. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med 2000 6 : 673 679.
33. Silver KL, Crockford TL, Bouriez-Jones T, Milling S, Lambe T, Cornall RJ. MyD88-dependent autoimmune disease in Lyn-deficient mice. Eur J Immunol 2007 37 : 2734 2743.
34. Sadanaga A, et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007 56 : 1618 1628.
35. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993 261 : 1328 1330.
36. Sadlack B, et al. Generalized autoimmune disease in interleukin-2- deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995 25 : 3053 3059.
37. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 1036.
38. Skupsky J, Su Y, Lei TC, Scott DW. Tolerance induction by gene transfer to lymphocytes. Curr Gene Ther 2007 7 : 369 380.
39. Kang Y, Melo M, Deng E, Tisch R, El-Amine M, Scott DW. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci USA 1999 96 : 8609 8614.
40. Litzinger MT, Su Y, Lei TC, Soukhareva N, Scott DW. Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction. J Immunol 2005 175 : 780 787.
41. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994 180 : 631 640.
42. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989 7 : 445 480.
43. El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 2000 165 : 5631 5636.
44. Zambidis ET, Barth RK, Scott DW. Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J Immunol 1997 158 : 2174 2182.
45. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 2000 106 : 245 252.
46. Melo ME, et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002 168 : 4788 4795.
47. Xu B, Scott DW. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol 2004 111 : 47 52.
48. Soukhareva N, Jiang Y, Scott DW. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol 2006 240 : 41 46.
49. Liang W, et al. B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis. Clin Immunol 2006 118 : 35 41.
50. Satpute SR, Soukhareva N, Scott DW, Moudgil KD. Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheum 2007 56 : 1490 1496.
51. Chen C, Rivera A, Ron N, Dougherty JP, Ron Y. A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 2001 97 : 886 894.
52. Chen CC, Rivera A, Dougherty JP, Ron Y. Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen. Blood 2004 103 : 4616 4618.
53. Kaufman DL, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993 366 : 69 72.
54. Blair PA, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009 182 : 3492 3502.
55. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003 102 : 956 963.
56. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003 101 : 4500 4504.
57. Lei TC, Su Y, Scott DW. Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. Cell Immunol 2005 235 : 12 20.
58. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, Mishra GC. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol 2003 170 : 5897 5911.
59. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001 19 : 595 621.
60. Rolink AG, Andersson J, Melchers F. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol 1998 28 : 3738 3748.
61. Rolink AG, Andersson J, Melchers F. Molecular mechanisms guiding late stages of B-cell development. Immunol Rev 2004 197 : 41 50.
62. Loder F, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999 190 : 75 89.
63. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001 167 : 6834 6840.
64. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002 32 : 04 10.
65. Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002 168 : 2101 2110.
66. Sonoda KH, Stein-Streilein J. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur J Immunol 2002 32 : 848 857.
67. Stein-Streilein J. Immune regulation and the eye. Trends Immunol 2008 29 : 548 554.
68. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005 26 : 347 362.
69. Cong YZ, Rabin E, Wortis HH. Treatment of murine CD5- B cells with anti-Ig, but not LPS, induces surface CD5: two B-cell activation pathways. Int Immunol 1991 3 : 467 476.
70. Vinuesa CG, et al. Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens. Eur J Immunol 2003 33 : 297 305.
71. Agenes F, Freitas AA. Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population. J Exp Med 1999 189 : 319 330.
72. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS. Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA 1999 96 : 13938 13943.
73. Dombrowicz D, et al. Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med 2001 193 : 25 34.
74. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008 118 : 3420 3430.
75. Makowska A, Faizunnessa NN, Anderson P, Midtvedt T, Cardell S. CD1high B cells: a population of mixed origin. Eur J Immunol 1999 29 : 3285 3294.
76. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008 28 : 639 650.
77. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009 182 : 7459 7472.
78. Evans JG, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007 178 : 7868 7878.
79. Yin Z, et al. IL-10 regulates murine lupus. J Immunol 2002 169 : 2148 2155.
80. Shimomura Y, et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol 2008 20 : 729 737.
81. Moritoki Y, et al. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 2009 136 : 1037 1047.
82. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001 13 : 195 201.
83. Madan R, et al. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J Immunol 2009 183 : 2312 2320.
84. Radhakrishnan S, et al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 2008 181 : 3137 3147.
85. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989 54 : 1 13.
86. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970 169 : 1042 1049.
87. Alon U. Network motifs: theory and experimental approaches. Nat Rev Genet 2007 8 : 450 461.
88. Alon U. Biological networks: the tinkerer as an engineer. Science 2003 301 : 1866 1867.
89. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci USA 2007 104 : 14080 14085.
90. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009 227 : 248 263.
91. Rubtsov AV, Swanson CL, Troy S, Strauch P, Pelanda R, Torres RM. TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. J Immunol 2008 180 : 3882 3888.
92. Pancer Z. Dynamic expression of multiple scavenger receptor cysteine-rich genes in coelomocytes of the purple sea urchin. Proc Natl Acad Sci USA 2000 97 : 13156 13161.
93. Hibino T, et al. The immune gene repertoire encoded in the purple sea urchin genome. Dev Biol 2006 300 : 349 365.
94. van der Aa LM, et al. A large new subset of TRIM genes highly diversified by duplication and positive selection in teleost fish. BMC Biol 2009 7 : 7.
95. Laing KJ, Purcell MK, Winton JR, Hansen JD. A genomic view of the NOD-like receptor family in teleost fish: identification of a novel NLR subfamily in zebrafish. BMC Evol Biol 2008 8 : 42.
96. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci 2008 114 : 347 360.
97. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 125C : 373 389.
98. Kitano H. Biological robustness. Nat Rev Genet 2004 5 : 826 837.
99. Scheffold A, Huhn J, Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 2005 35 : 1336 1341.
100. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006 441 : 235 238.
101. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008 64 : 187 199.
102. Velupillai P, Harn DA. Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets. Proc Natl Acad Sci USA 1994 91 : 18 22.
103. Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 2004 173 : 6346 6356.
104. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002 347 : 911 920.
105. Roelofs MF, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005 52 : 2313 2322.
106. Sacre SM, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007 170 : 518 525.
107. van der Heijden IM, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000 43 : 593 598.
108. Roelofs MF, et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006 176 : 7021 7027.
109. Midwood K, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009 15 : 774 780.
110. McPherson M, Wei B, Turovskaya O, Fujiwara D, Brewer S, Braun J. Colitis immunoregulation by CD8+ T cell requires T cell cytotoxicity and B cell peptide antigen presentation. Am J Physiol Gastrointest Liver Physiol 2008 295 : G485 G492.
111. Sugimoto K, Ogawa A, Shimomura Y, Nagahama K, Mizoguchi A, Bhan AK. Inducible IL-12-producing B cells regulate Th2-mediated intestinal inflammation. Gastroenterology 2007 133 : 124 136.
112. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989 110 : 135 149.
113. Mangan S, Itzkovitz S, Zaslaver A, Alon U. The incoherent feed-forward loop accelerates the response-time of the gal system of Escherichia coli. J Mol Biol 2006 356 : 1073 1081.
114. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007 131 : 1124 1136.
115. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001 293 : 306 311.
116. Hanada T, et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003 19 : 437 450.
117. Boone DL, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004 5 : 1052 1060.
118. Lee EG, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000 289 : 2350 2354.
119. Turer EE, et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 2008 205 : 451 464.